Therachon erhält den Orphan-Drug-Status der US FDA für Apraglutide zur Behandlung des Kurzdarmsyndroms

By In The News
January 16, 2019 in The Headlines

Recommended Posts

In The News

Posted January 16, 2019

- Share

Posted January 16, 2019

Zweiter Orphan-Drug-Status für Apraglutid, ein synthetisches GLP-2-Analogon der nächsten Generation mit dem potenziell besten Wirkungsprofil seiner Klasse vergeben BASEL, Schweiz, 16. Januar 2019 /PRNewswire/ -- Die Therachon AG („Therachon"), ein klinisch forschendes...

View the full article

Link to comment

Share on other sites

Archived

This topic is now archived and is closed to further replies.

Go to topic listing

Most Contributions
1. In The News
  217510
2. Jaydee
  15696
3. Kip Powick
  12016
4. deicer
  11466
5. dagger
  9586
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  267.6k
- Total Posts
  
  553.1k

Sign In

Therachon erhält den Orphan-Drug-Status der US FDA für Apraglutide zur Behandlung des Kurzdarmsyndroms

Recommended Posts

In The News

Link to comment

Share on other sites

Archived

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support